Title
Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis
A Phase 1b/2a, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AP-PA02 Multi-Phage Therapeutic Candidate for Inhalation in Subjects With Cystic Fibrosis and Chronic Pulmonary Pseudomonas Aeruginosa (Pa) Infection
Phase
Phase 1/Phase 2Lead Sponsor
Armata Pharmaceuticals, Inc.Study Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Cystic Fibrosis Pseudomonas Aeruginosa Pseudomonas Lung Infection Lung Infection PseudomonalIntervention/Treatment
AP-PA02 ...Study Participants
29Phase 1b/2a, double-blind, randomized, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability and phage recovery profile of AP-PA02 multi-bacteriophage therapeutic candidate administered by inhalation in subjects with cystic fibrosis and chronic pulmonary Pseudomonas aeruginosa (PA) infection.
The study consists of two parts. Subjects with Cystic Fibrosis and chronic pulmonary Pseudomonas aeruginosa (PA) infection will be enrolled in either Part 1 (single-ascending dose cohorts) or Part 2 (multiple-ascending dose cohorts).
Part 1 will evaluate single doses of AP-PA02 at two ascending dose levels, administered by inhalation. Treatment assignment will be randomized, double-blind, placebo-controlled in each of two ascending dose cohorts. Part 2 will also be double-blinded, randomized, placebo controlled, and will evaluate the safety and efficacy of multiple doses of AP-PA02 in each of two ascending dose level cohorts.
Subjects in both Parts 1 and 2 will be followed for approximately 4 weeks and evaluated for safety, tolerability, phage titer profile and immunogenicity.
Bacteriophage administered via inhalation
Inactive Placebo administered via inhalation
Key Inclusion Criteria: ≥ 18 years old Body mass index (BMI) of ≥ 18 kg/m2 Documented diagnosis of CF Evidence of chronic pulmonary Pseudomonas aeruginosa infection Willing to undergo sputum induction procedures at designated study visits, and willing to provide expectorated sputum samples at all other timepoints (for subjects who are able to expectorate) For SAD: FEV1 ≥ 60% of predicted normal [per Global Lung Function Initiative (GLI) standards] at Screening For MAD: FEV1 ≥ 40% of predicted normal [per Global Lung Function Initiative (GLI) standards] at Screening Adequate renal function Key Exclusion Criteria: Recent significant weight loss Abnormal vital signs at Screening History of prolonged QT syndrome Use of supplemental oxygen during the day at rest Abnormal liver function tests greater than 3X the upper limit of normal (ULN) Recent oral or IV antibiotics received for acute pulmonary exacerbation. Inhaled antibiotic use for chronic suppression of P. aeruginosa is acceptable. Recent clinically significant infection requiring systemic antimicrobial therapy Currently receiving anti-pseudomonal antibiotic treatment for acute sinusitis. Currently receiving systemic corticosteroids Currently receiving treatment for active infection with nontuberculous mycobacteria (NTM), Staphylococcus aureus, or Burkholderia cepacia complex lung infection Currently receiving treatment for aspergillosis or ABPA (allergic bronchopulmonary aspergillosis) Initiation of a CFTR potentiator/corrector therapy, such as Trikafta®, less than 90 days prior to Screening Acquired or primary immunodeficiency syndromes Active pulmonary malignancy (primary or metastatic) History of lung transplantation Recent hemoptysis Female pregnant or breastfeeding Heavy smoker
